TSHA
Taysha Gene Therapies, Inc.
Key Financials
Operating Income
$-110498000
↓ 20.8%
Net Income
$-108995000
↓ 22.1%
Total Assets
$343.3M
↑ 114.1%
Total Liabilities
$96.4M
↑ 8.5%
Revenue
$9.8M
↑ 17.3%
EPS (Diluted)
$-0.34
↑ 5.6%
Shareholders' Equity
$246.9M
↑ 245.2%
Cash & Equivalents
$319.8M
↑ 130.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/13/2026 | View on SEC |
| 10-Q | 8/11/2026 | View on SEC |
| 8-K | 8/11/2026 | View on SEC |
| 4 | 7/10/2026 | View on SEC |
| 144 | 7/10/2026 | View on SEC |
| 8-K | 6/25/2026 | View on SEC |
| 424B5 | 6/25/2026 | View on SEC |
| 424B5 | 6/24/2026 | View on SEC |
| 8-K | 6/22/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | TSHA |
| Company Name | Taysha Gene Therapies, Inc. |
| CIK | 1806310 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (214) 612-0000 |